Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

R Otto-Knapp

Showing results (11-20 of 22) with videos related to

Pageof 3
Sort By:
Pneumologie (Stuttgart, Germany)|May 15, 2019
[Joint Statement on the New WHO Recommendations for Treatment of Multidrug- and Rifampicin-Resistant Tuberculosis]F P Maurer, T Bauer, R Diel, et al.
Pneumologie (Stuttgart, Germany)|November 17, 2020
[The New WHO Guidelines for Rapid Diagnostics and Treatment of Drug-Resistant Tuberculosis Commented for Germany, Austria and Switzerland]R Otto-Knapp, M Knappik, B Häcker, et al.
IJTLD Open|January 19, 2026
Drug-resistant TB treatment outcomes and factors associated with discontinuation and LTFU in Germany: No1Lost study protocolM Gödecke, F Eberhardt, G Barten-Neiner, et al.
Pneumologie (Stuttgart, Germany)|February 18, 2021
Joint Statement (DZK, DGRh, DDG) on the Tuberculosis Risk with Treatment Using Novel Non-TNF-Alpha BiologicalsR Diel, T Schaberg, A Nienhaus, et al.
Pneumologie (Stuttgart, Germany)|July 17, 2020
[DZK Recommendations for Tuberculosis, BCG and COVID-19 in Germany - (Official Abbreviation of Coronavirus Disease 2019 Caused by the New Coronavirus SARS-CoV-2)]R Otto-Knapp, B Häcker, C Breuer, et al.
Pneumologie (Stuttgart, Germany)|July 10, 2014
[Resistance to second-line drugs in migrants with multidrug-resistant tuberculosis in the Berlin region]R Otto-Knapp, L Bös, N Schönfeld, et al.
Pneumologie (Stuttgart, Germany)|November 26, 2020
[Risk Assessment for Patients with Chronic Respiratory and Pulmonary Conditions in the Context of the SARS-CoV-2 Pandemic - Statement of the German Respiratory Society (DGP) with the Support of the German Association of Respiratory Physicians (BdP)]M Lommatzsch, K F Rabe, C Taube, et al.
IJTLD Open|March 17, 2025
Urgent request for pretomanid label expansion to align with WHO guidelines and improve treatment accessibility and efficacyL Kuksa, C Andrejak, B Haecker, et al.
IJTLD Open|June 18, 2025
Clinical best practices for caring for people with expanded resistance to newer TB drugsT Nkomo, Z Udwadia, D Vambe, et al.
IJTLD Open|May 13, 2026
Mental health management in the context of TB care in the WHO European Region: a consensus statementC Vilaplana, O Konstantynovska, O Rzhepishevska, et al.
Pageof 3

Showing results (11-20 of 22) with videos related to

Sort By:
Pageof 3
Pneumologie (Stuttgart, Germany)|May 15, 2019
[Joint Statement on the New WHO Recommendations for Treatment of Multidrug- and Rifampicin-Resistant Tuberculosis]F P Maurer, T Bauer, R Diel, et al.
Pneumologie (Stuttgart, Germany)|November 17, 2020
[The New WHO Guidelines for Rapid Diagnostics and Treatment of Drug-Resistant Tuberculosis Commented for Germany, Austria and Switzerland]R Otto-Knapp, M Knappik, B Häcker, et al.
IJTLD Open|January 19, 2026
Drug-resistant TB treatment outcomes and factors associated with discontinuation and LTFU in Germany: No1Lost study protocolM Gödecke, F Eberhardt, G Barten-Neiner, et al.
Pneumologie (Stuttgart, Germany)|February 18, 2021
Joint Statement (DZK, DGRh, DDG) on the Tuberculosis Risk with Treatment Using Novel Non-TNF-Alpha BiologicalsR Diel, T Schaberg, A Nienhaus, et al.
Pneumologie (Stuttgart, Germany)|July 17, 2020
[DZK Recommendations for Tuberculosis, BCG and COVID-19 in Germany - (Official Abbreviation of Coronavirus Disease 2019 Caused by the New Coronavirus SARS-CoV-2)]R Otto-Knapp, B Häcker, C Breuer, et al.
Pneumologie (Stuttgart, Germany)|July 10, 2014
[Resistance to second-line drugs in migrants with multidrug-resistant tuberculosis in the Berlin region]R Otto-Knapp, L Bös, N Schönfeld, et al.
Pneumologie (Stuttgart, Germany)|November 26, 2020
[Risk Assessment for Patients with Chronic Respiratory and Pulmonary Conditions in the Context of the SARS-CoV-2 Pandemic - Statement of the German Respiratory Society (DGP) with the Support of the German Association of Respiratory Physicians (BdP)]M Lommatzsch, K F Rabe, C Taube, et al.
IJTLD Open|March 17, 2025
Urgent request for pretomanid label expansion to align with WHO guidelines and improve treatment accessibility and efficacyL Kuksa, C Andrejak, B Haecker, et al.
IJTLD Open|June 18, 2025
Clinical best practices for caring for people with expanded resistance to newer TB drugsT Nkomo, Z Udwadia, D Vambe, et al.
IJTLD Open|May 13, 2026
Mental health management in the context of TB care in the WHO European Region: a consensus statementC Vilaplana, O Konstantynovska, O Rzhepishevska, et al.
Pageof 3